Structure Therapeutics Inc (GPCR)

$67.06 -0.38 (-0.56%)
Market Cap 3.88B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,503,900
Avg Vol 1,585,368
Day's Range N/A - N/A
Shares Out 57.80M
Stochastic %K 56%
Beta -1.64
Analysts Strong Sell
Price Target $97.15

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
RunnerSignals
RunnerSignals Dec. 13 at 10:47 AM
$CMPX $BRZE $GPCR $OMAB $FOLD show big upside on paper, the real game is timing. Charts are starting to talk before headlines do. Worth a closer look https://stocksrunner.com/target-price-changed
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 9:16 PM
$GPCR Current Stock Price: $67.05 Contracts to trade: $65 GPCR Dec 19 2025 Call Entry: $3.50 Exit: $6.90 ROI: 97% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:14 PM
Morgan Stanley has adjusted their stance on Structure Therapeutics ( $GPCR ), setting the rating to Overweight with a target price of 120 → 125.
0 · Reply
keylimepie2
keylimepie2 Dec. 12 at 2:15 PM
$GPCR
0 · Reply
Wallst45
Wallst45 Dec. 12 at 1:24 PM
$GPCR getting bought out yet ??
1 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 12:54 PM
Citizens has adjusted their stance on Structure Therapeutics ( $GPCR ), setting the rating to Market Outperform with a target price of 87 → 120.
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:09 PM
Citizens⬆️ $GPCR's PT to $120 from $87 and reiterated at a Market Outperform rating. $LLY $VKTX $NVO $AMGN PFE Here's what Citizens had to say in its note to investors: https://x.com/Quantumup1/status/1999450275493339515?s=20
0 · Reply
CattleFarmerJ
CattleFarmerJ Dec. 12 at 12:44 AM
$GPCR have 3600 at 19 dollar avg im not even thinking of selling till min 140
0 · Reply
Chamcham34
Chamcham34 Dec. 12 at 12:09 AM
$VKTX bet $NVO acquires $GPCR now. Stil la chance for $VKTX but probably big disconnect on value and bp trying to discount oral because of the safety issues
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 7:28 PM
Jefferies has updated their rating for Structure Therapeutics ( $GPCR ) to Buy with a price target of 125.
0 · Reply
Latest News on GPCR
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 2 days ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 4 days ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 9, 2025, 8:30 AM EST - 4 days ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Dec 8, 2025, 7:55 PM EST - 5 days ago

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 7:27 PM EST - 5 days ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 5:18 PM EST - 5 days ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 5 days ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 12:46 PM EST - 5 days ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 5 days ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 5 days ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 5 days ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 6 days ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 4 weeks ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 5 weeks ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 5 weeks ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

This Under-the-Radar Healthcare Stock Could Soar in 2026

Sep 12, 2025, 8:15 AM EDT - 3 months ago

This Under-the-Radar Healthcare Stock Could Soar in 2026

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 3 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 4 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 6 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 6 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 8 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 9 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 9 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 9 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 9 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Why Structure Therapeutics Stock Was Stumbling This Week

Feb 14, 2025, 7:56 AM EST - 10 months ago

Why Structure Therapeutics Stock Was Stumbling This Week

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 11 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Jul 22, 2024, 9:20 AM EDT - 1 year ago

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

VKTX

Could Structure Therapeutics Become the Next Novo Nordisk?

Jun 17, 2024, 9:53 AM EDT - 1 year ago

Could Structure Therapeutics Become the Next Novo Nordisk?

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

Jun 11, 2024, 4:57 AM EDT - 1 year ago

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?

Jun 9, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

RunnerSignals
RunnerSignals Dec. 13 at 10:47 AM
$CMPX $BRZE $GPCR $OMAB $FOLD show big upside on paper, the real game is timing. Charts are starting to talk before headlines do. Worth a closer look https://stocksrunner.com/target-price-changed
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 9:16 PM
$GPCR Current Stock Price: $67.05 Contracts to trade: $65 GPCR Dec 19 2025 Call Entry: $3.50 Exit: $6.90 ROI: 97% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:14 PM
Morgan Stanley has adjusted their stance on Structure Therapeutics ( $GPCR ), setting the rating to Overweight with a target price of 120 → 125.
0 · Reply
keylimepie2
keylimepie2 Dec. 12 at 2:15 PM
$GPCR
0 · Reply
Wallst45
Wallst45 Dec. 12 at 1:24 PM
$GPCR getting bought out yet ??
1 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 12:54 PM
Citizens has adjusted their stance on Structure Therapeutics ( $GPCR ), setting the rating to Market Outperform with a target price of 87 → 120.
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:09 PM
Citizens⬆️ $GPCR's PT to $120 from $87 and reiterated at a Market Outperform rating. $LLY $VKTX $NVO $AMGN PFE Here's what Citizens had to say in its note to investors: https://x.com/Quantumup1/status/1999450275493339515?s=20
0 · Reply
CattleFarmerJ
CattleFarmerJ Dec. 12 at 12:44 AM
$GPCR have 3600 at 19 dollar avg im not even thinking of selling till min 140
0 · Reply
Chamcham34
Chamcham34 Dec. 12 at 12:09 AM
$VKTX bet $NVO acquires $GPCR now. Stil la chance for $VKTX but probably big disconnect on value and bp trying to discount oral because of the safety issues
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 7:28 PM
Jefferies has updated their rating for Structure Therapeutics ( $GPCR ) to Buy with a price target of 125.
0 · Reply
calebprice_17
calebprice_17 Dec. 11 at 5:47 PM
$GPCR drug discovery focused on GPCR targets, pipeline progress is everything for valuation
0 · Reply
biolover
biolover Dec. 11 at 12:48 PM
$LLY $NVO $VKTX $LLY retatrutide DC rate of 18% is c/w what is seen in phase 2 .. also Lilly needs to disclose total DC rate.. ( in phase 2 below DC ready due to side effects 16% but total drug DC rate was 26 % ( below ) Lilly gives a hint that some of that could have been due to excessive weight loss but it’s unfair that Lilly does not provide DC rate due to GI side effects It has to mature more and stop hiding date like soapy companies ( Metsera ) $GPCR disclosed everything they could in phase 2
1 · Reply
lovelylee
lovelylee Dec. 11 at 12:43 PM
$CRBP $GPCR and it ran to 90+
0 · Reply
norbertm
norbertm Dec. 11 at 12:34 PM
$GPCR first target for me is taking out the intraday 95$ hit earlier this week.
0 · Reply
Trader1141
Trader1141 Dec. 11 at 12:27 PM
$CRBP phase 1 results like $GPCR 😎
0 · Reply
Wallst45
Wallst45 Dec. 11 at 11:16 AM
$GPCR this becomes a buyout target ?
0 · Reply
u_R_a_bagholder
u_R_a_bagholder Dec. 11 at 3:57 AM
$GPCR held up well, interested in the long side
0 · Reply
AutumnLee
AutumnLee Dec. 11 at 3:16 AM
👉 @AutumnLee 👀 Homepage $GPCR is +110% in 5 days on excellent GLP1 results 🚀 🔴 $LLY -5% 🔴 NVO -3% It seems the GLP1 wars are heating up, and at this valuation, trading for a P/E of 50 $LLY has more to lose. $NVO at 15 P/E is already low, but it can always fall more.
0 · Reply
mdrins00
mdrins00 Dec. 10 at 10:12 PM
$GPCR Priced $650M at $65
0 · Reply
Flyhalftrader
Flyhalftrader Dec. 10 at 8:57 PM
$VKTX good things coming here. $GPCR ‘s data helps and the fact that stock price is staying above offering price is good, and further helps us Vikings!
0 · Reply
Chamcham34
Chamcham34 Dec. 10 at 8:11 PM
$VKTX some explain how we have similar MC to $GPCR . We should be $6B atleast
1 · Reply
mj_ryder
mj_ryder Dec. 10 at 5:25 PM
$GPCR Not just in one day, it will get back to $50 once the hype is over which seems to be, as the volume dropped significantly and price unable to break and hold $70/75 levels multiple times. It will flush once it looses $60. However got long time on options to expire.
0 · Reply